Sona Nanotech Inc.

Supreme Court of Nova ScotiaCommencement Date: December 18, 2020


This is a proposed securities class action against Sona Nanotech Inc. and certain of its directors and officers. This class action alleges that Sona and the individual Defendants made misrepresentations and engaged in oppressive conduct in connection with Sona’s development of a COVID-19 antigen test and the submission of the test for approval by Health Canada as well as the United States Food and Drug Administration (FDA).

Specifically, this lawsuit alleges that the Defendants made misrepresentations in Sona’s Management Discussion and Analysis (MD&A) which was released on September 29, 2020, by improperly omitting the fact that Sona’s submissions to Health Canada and the FDA were not supported by appropriate data from independent clinical evaluation studies as required by the respective regulators. Furthermore, this MD&A omitted the fact that Sona’s clinical study was tainted by lack of independence, and its results were questionable, inaccurate or unreliable as a result of its lack of independence and because it was not carried out in accordance with the regulators’ guidelines and requirements. Because Sona’s submissions to Health Canada and the FDA were not supported by appropriate data, there was a heightened likelihood that Sona’s COVID-19 test would not be approved, which it ultimately was not.

Class Membership Criteria

This class action is brought on behalf of:

  • All persons and entities (except certain Excluded Persons), wherever they may reside or may be domiciled, who purchased or otherwise acquired common shares of Sona Nanotech Inc. during the period of time from September 29, 2020 to November 30, 2020, and who held some or all of those common shares as of October 29, 2020, November 25, 2020, or November 30, 2020.


March 23, 2022: Hearing of the leave and certification motion is scheduled for July 2022.


For the shares purchased during the identified "class period", those shares are automatically considered to be included within the proceeding. For shares purchased outside of the identified "class period", those are not automatically included and you may be required to retain your own lawyer.

We welcome you to complete the below form so you can receive future updates about the proceeding. If you invested more than $50,000, in the particular investment, please complete the form and we will contact you within the near future.

How to Reach Us

If you have a pressing legal issue, our lawyers can help:

Suite 401, Yonge Eglinton Centre2300 Yonge StreetToronto, OntarioCanada M4P 1E4